Rani Therapeutics Holdings, Inc.
General ticker "RANI" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $33.4M (TTM average)
Rani Therapeutics Holdings, Inc. does not follow the US Stock Market performance with the rate: -4.5%.
Estimated limits based on current volatility of 2.5%: low 0.84$, high 0.88$
Factors to consider:
- Total employees count: 106 (-24.3%) as of 2024
- Company does not operate outside North America (retrieved using AI)
- Top business risk factors: Operating losses, R&D failure, Market competition, Regulatory and compliance, Capital shortage
- Current price 15.1% below estimated low
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.01$, 3.16$]
- 2026-12-31 to 2027-12-31 estimated range: [1.03$, 3.10$]
Financial Metrics affecting the RANI estimates:
- Positive: with PPE of -2.4 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -19.97 <= 0.28
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: 42.26 < Shareholder equity ratio, % of 56.31 <= 63.63
- Positive: Inventory ratio change, % of -80.71 <= -0.75
- Negative: negative Net income
- Positive: Interest expense per share per price, % of 3.08 <= 3.34
Short-term RANI quotes
Long-term RANI plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $1.03MM | $1.63MM |
| Operating Expenses | $66.10MM | $54.34MM | $39.94MM |
| Operating Income | $-66.10MM | $-53.31MM | $-38.31MM |
| Non-Operating Income | $-1.78MM | $-3.27MM | $-2.64MM |
| Interest Expense | $5.08MM | $5.03MM | $2.89MM |
| R&D Expense | $39.62MM | $26.68MM | $20.20MM |
| Income(Loss) | $-67.88MM | $-56.58MM | $-40.95MM |
| Net Income(Loss)* | $-33.97MM | $-30.02MM | $-29.67MM |
| Stockholders Equity | $12.87MM | $1.99MM | $33.01MM |
| Assets | $57.92MM | $36.63MM | $58.62MM |
| Operating Cash Flow | $-51.24MM | $-35.50MM | $-18.71MM |
| Capital expenditure | $1.23MM | $0.27MM | $0.09MM |
| Investing Cash Flow | $29.86MM | $19.81MM | $-7.03MM |
| Financing Cash Flow | $0.23MM | $13.59MM | $40.30MM |
| Earnings Per Share** | $-1.33 | $-1.05 | $-0.45 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.